Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese.

Journal: Pharmacogenomics and personalized medicine
Published Date: Dec 31, 2019

Abstract

BACKGROUND: Previous studies suggest gliclazide is metabolised primarily by CYP2C19 rather than CYP2C9, unlike other sulphonylureas. and polymorphisms are more common in Asians.

Authors

  • Elaine Chow
    Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong.
  • Emily Wm Poon
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
  • Benny Sp Fok
    Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong.
  • Juliana Cn Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
  • Brian Tomlinson
    Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals